痛风发作相关的代谢组学特征:一项痛风患者的前瞻性研究
研究连续纳入痛风患者,横断面比较急性发作组与发作间期组的血清代谢组,并对发作间期组前瞻随访1年,分析复发发作者与无发作者。急性与发作间期组代谢谱不同,涉及碳水化合物、脂质和核苷酸代谢。由6个LASSO衍生代谢物构成的代谢风险评分对痛风发作风险的AUC为0.82(95%CI 0.74至0.90)。
要点
- 急性发作组与发作间期组代谢谱不同,涉及碳水化合物、脂质和核苷酸代谢。
- 含5-甲氧基色胺等6个LASSO衍生代谢物的代谢风险评分预测痛风发作风险AUC为0.82(95%CI 0.74至0.90)。
- 机器学习模型区分急性与发作间期组AUC为0.828;联合代谢物与临床指标预测复发发作AUC达0.807至0.867。
核心结论
- 代谢重编程可区分痛风的急性期与发作间期,所涉及的代谢物可能作为未来痛风发作的生物标志物。
研究设计与样本
- 前瞻性研究,连续纳入痛风患者,按入组时有无痛风发作分为急性组与发作间期组进行横断面分析。
- 发作间期组前瞻随访1年,按是否出现痛风复发分为复发发作组与无发作组进行分析。
- 基线血清代谢物相对丰度采用非靶向液相色谱-质谱联用测定,发作风险采用LASSO-Cox回归和时间ROC分析,并在独立验证队列中用定量靶向代谢组学进一步优化。
主要发现
- 急性组与发作间期组代谢谱不同,涉及碳水化合物、脂质和核苷酸代谢。
- 前瞻分析中多种代谢物与痛风复发发作相关。
- 含5-甲氧基色胺等6个LASSO衍生代谢物的代谢风险评分对痛风发作风险区分良好,AUC为0.82(95%CI 0.74至0.90)。
- 机器学习模型比较急性组与发作间期组的AUC为0.828。
- 联合代谢物与临床指标预测复发发作的AUC达0.807至0.867。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify specific metabolomic profiles associated with gout flares in people with gout. METHODS: Participants with gout were sequentially enrolled. In cross-sectional analysis, data were analysed according to the presence of gout flare (acute group) or absence of gout flare (intercritical group) at the time of enrolment. Participants in the intercritical group were prospectively followed and analysed according to the development of gout flares (recurrent flare group) or no gout flare (no flare group) over 1 year. Relative abundances of metabolites in serum obtained at the baseline visit were measured by untargeted liquid chromatography-mass spectrometry. Risk of incident flare was analysed using least absolute shrinkage and selection operator (LASSO)-Cox regression and time-receiver operating characteristic (ROC). Machine learning models were performed to identify biomarkers in cross-sectional and longitudinal analysis, which was further optimised using quantitative targeted metabolomics in an independent validation cohort. RESULTS: Participants in the acute and intercritical groups showed distinct metabolic profiles, including carbohydrate, lipid and nucleotide metabolism. Many metabolites were associated with recurrent gout flare in the prospective analysis. The metabolic risk score with six LASSO-derived metabolites, including 5-methoxytryptamine, differentiated well for gout flare risk, yielding an area under the ROC curve (AUC) of 0.82 (95% CI 0.74 to 0.90). Machine learning models achieved an AUC of 0.828 for comparison between the acute and intercritical groups. For the prediction of recurrent flare, AUC reached 0.807-0.867 with combined metabolites and clinical measurements. CONCLUSIONS: Metabolic reprogramming differentiates between the acute and intercritical stages of gout, and implicated metabolites may serve as biomarkers for future gout flares.
引用
- Sun W, Li R, Dalbeth N, et al. Metabolomic profiles underlying gout flares: a prospective study of people with gout. RMD Open. 2025. PMID: 40345707. doi:10.1136/rmdopen-2024-005278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。